NCT05502250 2026-03-06
HOVON164HL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04282018 2026-02-20
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeOne Medicines
Phase 1/2 Completed
NCT07418190 2026-02-18
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04425070 2026-01-05
TOUCH
Antengene Corporation
Phase 1/2 Terminated
NCT05977673 2025-12-08
FIL_Tisle-HL
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT04170283 2025-10-21
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT05267054 2025-09-15
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
BeiGene
Phase 1/2 Completed
NCT07031700 2025-06-22
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04261439 2025-05-06
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Phase 1 Terminated